Role of DNA Methylation in the Pathogenesis and Treatment of Myelodysplastic Syndromes

Seminars in Hematology

Volumn 50, Issue 1, 2013, Pages 16-37

  Khan, Hina ^a   Vale, Cristina ^a   Bhagat, Tushar ^a   Verma, Amit ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA CATENIN; AZACITIDINE; BUTYRIC ACID; CYCLIN DEPENDENT KINASE INHIBITOR 1C; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DEATH ASSOCIATED PROTEIN KINASE; DNA; DNA METHYLTRANSFERASE INHIBITOR; ENTINOSTAT; SUPPRESSOR OF CYTOKINE SIGNALING 1; UVOMORULIN; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CANCER STEM CELL; CDH1 GENE; CELL CYCLE REGULATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL TRIAL (TOPIC); CTNNA1 GENE; DAPK1 GENE; DNA METHYLATION; DNA REPAIR; DRUG APPROVAL; DRUG CYTOTOXICITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; EPIGENETICS; FRAGILE HISTIDINE TRIAD GENE; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE MUTATION; GENE SILENCING; GENOME ANALYSIS; HIGH RISK PATIENT; HUMAN; LEUKEMOGENESIS; LOW DRUG DOSE; LOW RISK POPULATION; MALIGNANT TRANSFORMATION; MICROARRAY ANALYSIS; MOLECULAR PATHOLOGY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; P15INK4B GENE; P57KIP2 GENE; PHARMACOGENETICS; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; DNA; DNA METHYLATION; DNA MODIFICATION METHYLASES; ENZYME INHIBITORS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MYELODYSPLASTIC SYNDROMES;

EID: 84875312162     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2013.01.001     Document Type: Article

References (139)

1. Steensma D.P., Tefferi A. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res 2003, 27(2):95-120.
2. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128(4):683-692.
3. Herman J.G., Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003, 349:2042-2054.
4. Fenton R.G., Longo D.L. Cancer cell biology and angiogenesis. Harrison's principles of internal medicine 2005, 453-464. McGraw-Hill, New York. 16th ed. D.L. Kasper, E. Braunwald, A.S. Fauci, S.L. Hauser, D.L. Longo, J.L. Jameson (Eds.).
5. Jones P.A., Liang G. Rethinking how DNA methylation patterns are maintained. Nat Rev Genet 2009, 10(11):805-811.
6. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002, 16(1):6-21.
7. Figueroa M.E., Wouters B.J., Skrabanek L., et al. Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features. Blood 2009, 113(12):2795-2804.
8. Irizarry R.A., Ladd-Acosta C., Wen B., et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009, 41(2):178-186.
9. Zhou L., Opalinska J., Sohal D., et al. Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q. J Biol Chem 2011, 286(28):25211-25223.
10. Okano M., Bell D.W., Haber D.A., Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999, 99:247-257.
11. Bourc'his D., Xu G.L., Lin C.S., Bollman B., Bestor T.H. Dnmt3L and the establishment of maternal genomic imprints. Science 2001, 294(5551):2536-2539.
12. Jia D., Jurkowska R.Z., Zhang X., Jeltsch A., Cheng X. Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA methylation. Nature 2007, 449:248-251.
13. Kautiainen T.L., Jones P.A. Dna methyltransferase levels in tumorigenic and nontumorigenic cells in culture. J Biol Chem 1986, 261(4):1594-1598.
14. Rhee I., Bachman K.E., Park B.H., et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002, 416(6880):552-556.
15. Hopfer O., Komor M., Koehler I.S., et al. Aberrant promotor methylation in MDS hematopoietic cells during in vitro lineage specific differentiation is differently associated with DNMT isoforms. Leuk Res 2009, 33(3):434-442.
16. Eden A., Gaudet F., Waghmare A., Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003, 300(5618):455.
17. Pogribny I.P., Beland F.A. DNA hypomethylation in the origin and pathogenesis of human diseases. Cell Mol Life Sci 2009, 66:2249-2261.
18. Wu H., Chen Y., Liang J., et al. Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis. Nature 2005, 438(7070):981-987.
19. Lin J., Yao D.M., Qian J., et al. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with myelodysplastic syndrome. Leuk Res 2008, 32:1541-1545.
20. Iwai M., Kiyoi H., Ozeki K., et al. Expression and methylation status of the FHIT gene in acute myeloid leukemia and myelodysplastic syndrome. Leukemia 2005, 19:1367-1375.
21. Valencia A., Cervera J., Such E., et al. Aberrant methylation of tumor suppressor genes in patients with refractory anemia with ring sideroblasts. Leuk Res 2011, 35(4):479-483.
22. Raj K., John A., Ho A., et al. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia 2007, 21(9):1937-1944.
23. Christiansen D.H., Andersen M.K., Pedersen-Bjergaard J. Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2003, 17(9):1813-1819.
24. Au W.Y., Fung A., Man C., et al. Aberrant p15 gene promoter methylation in therapy-related myelodysplastic syndrome and acute myeloid leukaemia: clinicopathological and karyotypic associations. Br J Haematol 2003, 120(6):1062-1065.
25. Chen H., Wu S. Hypermethylation of the p15(INK4B) gene in acute leukemia and myelodysplastic syndromes. Chin Med J (Engl) 2002, 115(7):987-990.
26. Preisler H.D., Li B., Chen H., et al. P15INK4B gene methylation and expression in normal, myelodysplastic, and acute myelogenous leukemia cells and in the marrow cells of cured lymphoma patients. Leukemia 2001, 15(10):1589-1595.
27. Tien H.F., Tang J.H., Tsay W., et al. Methylation of the p15(INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. Br J Haematol 2001, 112:148-154.
28. Aoki E., Uchida T., Ohashi H., et al. Methylation status of the p15INK4B gene in hematopoietic progenitors and peripheral blood cells in myelodysplastic syndromes. Leukemia 2000, 14(4):586-593.
29. Quesnel B., Guillerm G., Vereecque R., et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998, 91(8):2985-2990.
30. Uchida T., Kinoshita T., Nagai H., et al. Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood 1997, 90(4):1403-1409.
31. Aoki E., Ohashi H., Uchida T., Murate T., Saito H., Kinoshita T. Expression levels of DNA methyltransferase genes do not correlate with p15INK4B gene methylation in myelodysplastic syndromes. Leukemia 2003, 17:1903-1904.
32. Berg T., Guo Y., Abdelkarim M., Fliegauf M., Lübbert M. Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines. Leuk Res 2007, 31(4):497-506.
33. Tessema M., Länger F., Dingemann J., Ganser A., Kreipe H., Lehmann U. Aberrant methylation and impaired expression of the p15(INK4b) cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML). Leukemia 2003, 17(5):910-918.
34. Teofili L., Martini M., Di Mario A., et al. Expression of p15(ink4b) gene during megakaryocytic differentiation of normal and myelodysplastic hematopoietic progenitors. Blood 2001, 98(2):495-497.
35. Kim M., Oh B., Kim S.Y., et al. p15INK4b methylation correlates with thrombocytopenia, blast percentage, and survival in myelodysplastic syndromes in a dose dependent manner: quantitation using pyrosequencing study. Leuk Res 2010, 34(6):718-722.
36. Huang T.C., Ko B.S., Tang J.L., et al. Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies. Leukemia 2008, 22(3):544-550.
37. Brakensiek K., Länger F., Schlegelberger B., Kreipe H., Lehmann U. Hypermethylation of the suppressor of cytokine signalling-1 (SOCS-1) in myelodysplastic syndrome. Br J Haematol 2005, 130(2):209-217.
38. Johan M.F., Bowen D.T., Frew M.E., Goodeve A.C., Reilly J.T. Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 2005, 129(1):60-65.
39. Boumber Y.A., Kondo Y., Chen X., et al. RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis. Cancer Res 2007, 67(5):1997-2005.
40. Liu T.X., Becker M.W., Jelinek J., et al. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med 2007, 13(1):78-83.
41. Desmond J.C., Raynaud S., Tung E., Hofmann W.K., Haferlach T., Koeffler H.P. Discovery of epigenetically silenced genes in acute myeloid leukemias. Leukemia 2007, 21(5):1026-1034.
42. Ye Y., McDevitt M.A., Guo M., et al. Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies. Cancer Res 2009, 69(21):8482-8490.
43. Brakensiek K., Länger F., Kreipe H., Lehmann U. Absence of p21(CIP 1), p27(KIP 1) and p57(KIP 2) methylation in MDS and AML. Leuk Res 2005, 29(11):1357-1360.
44. Li Y., Nagai H., Ohno T., et al. Aberrant DNA methylation of p57(KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype. Blood 2002, 100(7):2572-2577.
45. Sheikhha M.H., Tobal K., Liu Yin J.A. High level of microsatellite instability but not hypermethylation of mismatch repair genes in therapy-related and secondary acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol 2002, 117(2):359-365.
46. Ohashi H., Tsushita K., Utsumi M., et al. Relationship between methylation of the p15 gene and ectopic expression of the EVI-1 gene in myelodysplastic syndromes (MDS). Leukemia 2001, 15(6):990-991.
47. Russell M., List A., Greenberg P., et al. Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations. Blood 1994, 84(4):1243-1248.
48. Voso M.T., Scardocci A., Guidi F., et al. Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes. Blood 2004, 103(2):698-700.
49. Dhodapkar M., Grill J., Lust J.A. Abnormal regional hypermethylation of the calcitonin gene in myelodysplastic syndromes. Leuk R.es 1995, 19(10):719-726.
50. Claus R., Hackanson B., Poetsch A.R., et al. Quantitative analyses of DAPK1 methylation in AML and MDS. Int J Cancer 2012, 131(2):E138-E142. Epub 2011 Sep 14.
51. Qian J., Yao D.M., Lin J., et al. Methylation of DAPK1 promoter: frequent but not an adverse prognostic factor in myelodysplastic syndrome. Int J Lab Hematol 2010, 32(1 Pt 2):74-81.
52. Wu X., Liu W., Tian Y., Xiao M., Wu Y., Li C. Aberrant methylation of death-associated protein kinase 1 CpG islands in myelodysplastic syndromes. Acta Haematol 2011, 125(4):179-185.
53. Lin J., Wang Y.L., Qian J., et al. Aberrant methylation of DNA-damage-inducible transcript 3 promoter is a common event in patients with myelodysplastic syndrome. Leuk Res 2010, 34(8):991-994.
54. Cheng Y.Y., Chau D., Chan T., et al. Absence of NPM1 promoter hypermethylation in human myelodysplastic syndrome. J Clin Pathol 2010, 63(11):1008-1011.
55. Benetatos L., Hatzimichael E., Dasoula A., et al. CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes. Leuk Res 2010, 34(2):148-153.
56. Potapova A., Hasemeier B., Römermann D., et al. Epigenetic inactivation of tumour suppressor gene KLF11 in myelodysplastic syndromes. Eur J Haematol 2010, 84(4):298-303.
57. Wang H., Wang X.Q., Xu X.P., Lin G.W. ID4 methylation predicts high risk of leukemic transformation in patients with myelodysplastic syndrome. Leuk Res 2010, 34(5):598-604.
58. Hopfer O., Nolte F., Mossner M., et al. Epigenetic dysregulation of GATA1 is involved in myelodysplastic syndromes dyserythropoiesis. Eur J Haematol 2012, 88(2):144-153.
59. Mori N., Yoshinaga K., Tomita K., et al. Aberrant methylation of the RIZ1 gene in myelodysplastic syndrome and acute myeloid leukemia. Leuk Res 2011, 35(4):516-521.
60. Borze I., Juvonen E., Ninomiya S., Jee K.J., Elonen E., Knuutila S. High-resolution oligonucleotide array comparative genomic hybridization study and methylation status of the RPS14 gene in de novo myelodysplastic syndromes. Cancer Genet Cytogenet 2010, 197(2):166-173.
61. Reins J., Mossner M., Neumann M., et al. Transcriptional down-regulation of the Wnt antagonist SFRP1 in haematopoietic cells of patients with different risk types of MDS. Leuk Res 2010, 34(12):1610-1616.
62. Benetatos L., Dasoula A., Hatzimichael E., et al. Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions. Ann Hematol 2011, 90(9):1037-1045.
63. Follo M.Y., Finelli C., Mongiorgi S., et al. Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Proc Natl Acad Sci U S A 2009, 106(39):16811-16816.
64. Solomon P.R., Munirajan A.K., Tsuchida N., et al. Promoter hypermethylation analysis in myelodysplastic syndromes: diagnostic & prognostic implication. Indian J Med Res 2008, 127(1):52-57.
65. Hofmann W.K., Takeuchi S., Takeuchi N., Thiel E., Hoelzer D., Koeffler H.P. Comparative analysis of hypermethylation of cell cycle control and DNA-mismatch repair genes in low-density and CD34+ bone marrow cells from patients with myelodysplastic syndrome. Leuk Res 2006, 30(11):1347-1353.
66. Aggerholm A., Holm M.S., Guldberg P., Olesen L.H., Hokland P. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol 2006, 76(1):23-32.
67. Grövdal M., Khan R., Aggerholm A., et al. Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome. Clin Cancer Res 2007, 13(23):7107-7112.
68. Greco M., D'Alò F., Scardocci A., et al. Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms. Blood Cells Mol Dis 2010, 45(3):181-185.
69. Figueroa M.E., Skrabanek L., Li Y., et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 2009, 114(16):3448-3458. 10.1182/blood-2009-01-200519.
70. Fuks F., Burgers W.A., Brehm A., Hughes-Davies L., Kouzarides T. DNA methyltransferase dnmt1 associates with histone deacetylase activity. Nat Genet 2000, 24(1):88-91.
71. Tessema M., Langer F., Dingemann J., Ganser A., Kreipe H., Lehmann U. Aberrant methylation and impaired expression of the p15(INK4b) cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML). Leukemia 2003, 17(5):910-918.
72. Brakensiek K., Langer F., Schlegelberger B., Kreipe H., Lehmann U. Hypermethylation of the suppressor of cytokine signalling-1 (SOCS-1) in myelodysplastic syndrome. Br J Haematol 2005, 130(2):209-217.
73. Christiansen D.H., Andersen M.K., Pedersen-Bjergaard J. Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2003, 17(9):1813-1819.
74. Aggerholm A., Holm M.S., Guldberg P., Olesen L.H., Hokland P. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol 2006, 76(1):23-32.
75. Jiang Ying, Dunbar Andrew, Lukasz P., et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009, 113(6):1315-1325.
76. Ohta M., Inoue H., Coticelli M.G., et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t (3; 8) breakpoint, is abnormal in digestive tract cancers. Cell 1996, 84:587-597.
77. Uchida T., Kinoshita T., Nagai H., et al. Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood 1997, 90(4):1403-1409.
78. Quesnel B., Guillerm G., Vereecque R., et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998, 91(8):2985-2990.
79. Tien H.F., Tang J.H., Tsay W., et al. Methylation of the p15(INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. Br J Haematol 2001, 112(1):148-154.
80. Au W.Y., Fung A., Man C., et al. Aberrant p15 gene promoter methylation in therapy-related myelodysplastic syndrome and acute myeloid leukaemia: clinicopathological and karyotypic associations. Br J Haematol 2003, 120(6):1062-1065.
81. Alexander W.S. Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol 2002, 2:410-416.
82. Ekmekci C.G., Gultierrez M.I., Siraj A.K., et al. Aberrant methylation of multiple tumor suppressor genes in acute myeloid leukemia. Am J Haematol 2004, 77:233-240.
83. Baylin S.B., Herman J.G. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000, 16:168-174.
84. Komrokji R.S., Bennett J.M. Evolving classifications of the myelodysplastic syndromes. Curr Opin Hematol 2007, 14:98-105.
85. Lin J., Yao D.M., Qian J., et al. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with myelodysplastic syndrome. Leuk Res 2008, 32:1541-1545.
86. Wu S.J., Yao M., Chou W.C., et al. Clinical implications of SOCS1 methylation in myelodysplastic syndrome. Br J Haematol 2006, 135:317-323.
87. Grovdal M., Khan R., Aggerholm A., et al. Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome. Clin Cancer Res 2007, 13:7107-7112.
88. Benetatos L., Hatzimichael E., Dasoula A., et al. CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukaemia and myelodysplastic syndromes. Leukemia Res 2010, 34(2):148-153. In press.
89. Shen L., Kantarjian H., Guo Y., et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010, 28(4):605-613.
90. Walter M.J., Ding L., Shen D., et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011, 25(7):1153-1158.
91. Ko M., Huang Y., Jankowska A.M., et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010, 468(7325):839-843.
92. Figueroa M.E., Abdel-Wahab O., Lu C., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18(6):553-567.
93. Jankowska A.M., Shaik M., Cazzolli H., et al. Impact of TET2 mutations on responsiveness to demethylating agents in MDS. Blood (ASH Annual Meeting Abstracts) 2009, 114. abstract 1606.
94. Kaminskas E., Farrell A.T., Wang Y.C., Sridhara R., Pazdur R. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist 2005, 10:176-182.
95. Stresemann C., Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 2008, 123:8-13.
96. Li L.H., Olin E.J., Buskirk H.H., Reineke L.M. Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. Cancer Res 1970, 30:2760-2769.
97. Hollenbach P.W., Nguyen A.N., Brady H., et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One 2010, 5:e9001.
98. Silverman L.R., Demakos E.P., Peterson B.L., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 2002, 20:2429-2440.
99. Kantarjian H., Oki Y., Garcia-Manero G., et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007, 109(1):52-57.
100. Cheson B.D., Greenberg P.L., Bennett J.M., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108(2):419-425.
101. Silverman L.R., Fenaux P., Mufti G.J., et al. The effects of continued azacitidine (AZA) treatment cycles on response in higher-risk patients (pts) with myelodysplastic syndromes (MDS). Blood 2008, 112(11). abstract 227.
102. Yang A.S., Doshi K.D., Choi S.W., et al. DNA methylation changes after 5-aza-2-deoxycytidine therapy in patients with leukemia. Cancer Res 2006, 66(10):5495-5503.
103. Garcia-Manero G., Gore S.D., Cogle C.R., et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol 2011 Jun 20, 29(18):2521-2527.
104. Ghoshal K., Datta J., Majumder S., et al. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol Cell Biol 2005, 25:4727-4741.
105. Kuo H.K., Griffith J.D., Kreuzer K.N. 5-Azacytidine induced methyltransferase-DNA adducts block DNA replication in vivo. Cancer Res 2007, 67:8248-8254.
106. Momparler R.L. Pharmacology of 5-aza-2'-deoxycytidine(decitabine). Semin Hematol 2005, 42:S9-S16.
107. Santini V., Kantarjian H.M., Issa J.P. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med 2001, 134:573-586.
108. Kantarjian H., Issa J.P., Rosenfeld C.S., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006, 106:1794-1803.
109. Wijermans P., Suciu S., Baila L., et al. Low dose decitabine versus best supportive care in elderly patients with intermediate or high risk MDS not eligible for intensive chemotherapy: final results of the randomized phase III study (06011) of the EORTC Leukemia and German MDS Study Groups. Blood 2008, 112. abstract 226.
110. Tsai H.C., Li H., Van Neste L., et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 2012, 21(3):430-446.
111. Saunthararajah Y., Triozzi P., Rini B., et al. p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies. Semin Oncol 2012, 39(1):97-108.
112. Gore S.D., Baylin S., Sugar E., et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006, 66(12):6361-6369.
113. Daskalakis M., Nguyen T.T., Nguyen C., et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2-deoxycytidine (decitabine) treatment. Blood 2002, 100(8):2957-2964.
114. Issa J.P., Garcia-Manero G., Giles F.J., et al. Phase1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2_-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004, 103(5):1635-1640.
115. Raj K., John A., Ho A., et al. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia 2007, 21(9):1937-1944.
116. Garcia-Manero G., Kantarjian H.M., Sanchez-Gonzalez B., et al. Phase 1/2 study of the combination of 5-aza-2-deoxycytidine with valproic acid in patients with leukemia. Blood 2006, 108(10):3271-3279.
117. Fandy T.E., Herman J.G., Kerns P., et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009, 114(13):2764-2773.
118. Follo M.Y., Russo D., Finelli C., et al. Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment. Leukemia 2012, 26(5):943-950.
119. Herman J.G., Gore S.D., Mufti G.J., et al. Relationship among gene methylation, azacitidine treatment, and survival in patients with higher-risk myelodysplastic syndromes (MDS): results from the AZA-001 trial. AACR 2009, abstract 4746.
120. Itzykson R., Kosmider O., Cluzeau T., et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 2011, 25(7):1147-1152.
121. Pollyea D.A., Raval A., Kusler B., Gotlib J.R., Alizadeh A.A., Mitchell B.S. Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors. J Hematol Oncol 2011, 29(3):157-160.
122. Stewart D.J., Issa J.P., Kurzrock R., et al. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res 2009, 15:3881-3888.
123. Soriano A.O., Yang H., Faderl S., et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007, 110:2302-2308.
124. Braiteh F., Soriano A.O., Garcia-Manero G., et al. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin Cancer Res 2008, 14:6296-6301.
125. Fandy T.E., Herman J.G., Kerns P., Jiemjit A., Sugar E.A., Choi S.H., et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 2009, 114:2764-2773.
126. Blum W., Klisovic R.B., Hackanson B., et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 2007, 25:3884-3891.
127. Gollob J.A., Sciambi C.J., Peterson B.L., et al. Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Clin Cancer Res 2006, 12:4619-4627.
128. De Padua Silva L., de Lima M., Kantarjian H., et al. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant 2009, 43:839-843.
129. Garcia-Manero G., Kantarjian H.M., Sanchez-Gonzalez B., et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood 2006, 108:3271-3279.
130. Appleton K., Mackay H.J., Judson I., Plumb J.A., McCormick C., Strathdee G., et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 2007, 25:4603-4609.
131. Stresemann C., Bokelmann I., Mahlknecht U., Lyko F. Azacytidine causes complex DNA methylation responses in myeloid leukemia. Mol Cancer Ther 2008, 7(9):2998-3005.
132. Martin M.G., Walgren R.A., Procknow E., et al. A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes. Am J Hematol 2009, 84:560-564.
133. Sekeres M.A., List A.F., Cuthbertson D., et al. Phase I combination trial of lenalidomide and azacitidine in patients with higher risk myelodysplastic syndromes. J Clin Oncol 2010, 28:2253-2258.
134. Garcia-Manero G., Kantarjian H.M., Sanchez-Gonzalez B., et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood 2006, 108:3271-3279.
135. Blum W., Garzon R., Klisovic R.B., et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A 2010, 107:7473-7478.
136. Issa J.P., Kantarjian H.M. Targeting DNA methylation. Clin Cancer Res 2009, 15:3938-3946.
137. Qin T., Jelinek J., Si J., Shu J., Issa J.P. Mechanisms of resistance to 5-aza-29- deoxycytidine in human cancer cell lines. Blood 2009, 113:659-667.
138. Qin T., Castoro R., El Ahdab S., et al. Mechanisms of resistance to decitabine in the myelodysplastic syndrome. PLoS One 2011, 6(8):e23372.
139. Simó-Riudalbas L., Melo S.A., Esteller M. DNMT3B gene amplification predicts resistance to DNA demethylating drugs. Genes Chromosomes Cancer 2011, 50:527-534.